Morgan Stanley Maintains Equal-Weight on Rhythm Pharmaceuticals, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and raised the price target from $28 to $29.
October 10, 2023 | 3:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Rhythm Pharmaceuticals and raised the price target from $28 to $29.
The news is directly related to Rhythm Pharmaceuticals. The raised price target by Morgan Stanley indicates a positive outlook for the company, which could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100